All In Biotech

Drug Trial Radar · NCT06772870

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Feb 2025

Primary completion

Sep 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Design Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.

Conditions

  • Friedreich Ataxia

Interventions

  • DT-216P2Drug

    DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.

  • SalineDrug

    Normal saline solution will be used as placebo control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment emergent adverse events (TEAEs)Time frame: From first dose to end of study, Day 30 post first dose administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network, Level 5, 89 Commercial Road

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.